Melinta Therapeutics (MLNTQ) Stock Price, News & Analysis

Company Overview

Melinta Therapeutics is a specialty pharmaceutical company dedicated to the discovery, development and commercialization of novel antibiotics for the treatment of serious bacterial infections. The company’s primary focus is on addressing critical unmet medical needs in hospital and community settings, with an emphasis on complex skin and skin‐structure infections, pneumonia and complicated urinary tract infections.

Melinta markets two approved products: Baxdela® (delafloxacin), a fluoroquinolone antibiotic indicated for acute bacterial skin and skin‐structure infections and community-acquired bacterial pneumonia, and Vabomere® (meropenem-vaborbactam), a carbapenem‐beta-lactamase inhibitor combination approved for complicated urinary tract infections. In addition to these marketed therapies, Melinta’s pipeline includes both intravenous and oral antibiotic candidates designed to target multidrug‐resistant Gram-negative and Gram-positive pathogens.

Founded in 2011 and headquartered in New Haven, Connecticut, Melinta has built its business around strategic collaborations and in-licensing agreements to bolster its product portfolio and advance late-stage development programs. The company’s operations are primarily focused on the United States, where it works closely with hospitals, infectious disease specialists and healthcare providers to support stewardship and appropriate antibiotic use.

Key Stats

• Today's Range: $0.11 to $0.11
• 50-Day Range: $0.11 to $0.11
• 52-Week Range: $0.06 to $8.60
• Volume: 32,900 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MLNTQ
• CIK: N/A
• Web: www.melinta.com
• Phone: 908-617-1309
• Fax: N/A
• Employees: 290
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A